EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA Damage

Anell Fernandez iD, Maider Artola, Sergio Leon, Nerea Otegui iD, Aroa Jimeno, Diego Serrano iD, Alfonso Calvo iD

Cells · 20.05.2025 · 14 (10) · 748

DOI: 10.3390/cells14100748 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 20.05.2025. Verfasst von Anell Fernandez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Program in Solid Tumors, CIMA, Cancer Center Clinica Universidad de Navarra (CCUN), University of Navarra, Avenida de Pio XII, 55, 31008 Pamplona, Sp…. Hauptthemen laut MEDLINE: DNA Damage, Checkpoint Kinase 2, Ataxia Telangiectasia Mutated Proteins, Checkpoint Kinase 1. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III (ISCIII)-FIS Pl25/01059, World Wide Cancer Research, Gobierno de Navarra-GRANATE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eliciting DNA damage in tumor cells continues to be one of the most successful strategies against cancer. This is the case for classical chemotherapy drugs and radiotherapy. In the modern era of personalized medicine, this strategy tries to identify specific vulnerabilities found in each patient’s tumor, to inflict DNA damage in certain cell contexts that end up in massive cancer cell death. Cells rely on multiple DNA repair pathways to fix DNA damage, but cancer cells frequently exhibit defects in these pathways, many times being tolerant to the damage. Key vulnerabilities, such as BRCA1/BRCA2 mutations, have been exploited with PARP inhibitors, leveraging synthetic lethality to selectively kill tumor cells and improving patients’ survival. In the DNA damage response (DDR) network, kinases ATM, ATR, Chk1, and Chk2 coordinate DNA repair, cell cycle arrest, and apoptosis. Inhibiting these proteins enhances tumor sensitivity to DNA-damaging therapies, especially in DDR-deficient cancers. Several small-molecule inhibitors targeting ATM/Chk2 or ATR/Chk1 are currently being tested in preclinical and/or clinical settings, showing promise in cancer models and patients. Additionally, pharmacological blockade of ATM/Chk2 and ATR/Chk1 axes enhances the effects of immunotherapy by increasing tumor immunogenicity, promoting T-cell infiltration and activating immune responses. Combining ATM/Chk2- or ATR/Chk1-targeting drugs with conventional chemotherapy, radiotherapy or immune checkpoint inhibitors offers a compelling strategy to improve treatment efficacy, overcome resistance, and enhance patients’ survival in modern oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA DamageCheckpoint Kinase 2Ataxia Telangiectasia Mutated ProteinsCheckpoint Kinase 1NeoplasmsHumansDNA RepairAnimalsSignal Transduction

Stichwörter der Autor:innen

ATMATRChk1Chk2DNA damageimmunotherapysynthetic lethality

Substanzen

Checkpoint Kinase 2Ataxia Telangiectasia Mutated ProteinsCheckpoint Kinase 1ATR protein, humanCHEK2 protein, humanATM protein, humanCHEK1 protein, human

Autor:innen und Institutionen

  • Program in Solid Tumors, CIMA, Cancer Center Clinica Universidad de Navarra (CCUN), University of Navarra, Avenida de Pio XII, 55, 31008 Pamplona, Spain.
  • Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, 31008 Pamplona, Spain.
  • CIBERONC, ISCIII, 28029 Madrid, Spain.
  • IDISNA, 31008 Pamplona, Spain.

ORCID-Profile: Anell Fernandez, Nerea Otegui, Diego Serrano, Alfonso Calvo

Förderung

  • Instituto de Salud Carlos III (ISCIII)-FIS Pl25/01059
  • World Wide Cancer Research
  • Gobierno de Navarra-GRANATE
  • International Association for the Study of Lung Cancer
  • Asociación de Amigos, University of Navarra
  • Gobierno de Navarra

Zitieren

APA

Fernandez, A., Artola, M., Leon, S., Otegui, N., Jimeno, A., Serrano, D., & Calvo, A. (2025). Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA Damage. Cells, 14(10), 748. https://doi.org/10.3390/cells14100748

Vancouver

Fernandez A, Artola M, Leon S, Otegui N, Jimeno A, Serrano D, et al. Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA Damage. Cells. 2025;14(10):748. doi:10.3390/cells14100748

BibTeX
@article{Fernandez2025,
  author = {Fernandez, Anell and Artola, Maider and Leon, Sergio and Otegui, Nerea and Jimeno, Aroa and Serrano, Diego and Calvo, Alfonso},
  title = {Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA Damage},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {10},
  pages = {748},
  doi = {10.3390/cells14100748}
}
Kostenlos starten →